Sato, Akihiro
Kato, Takao
Kasai, Takatoshi http://orcid.org/0000-0001-5747-7668
Ishiwata, Sayaki
Yatsu, Shoichiro
Matsumoto, Hiroki
Shitara, Jun
Murata, Azusa
Shimizu, Megumi
Suda, Shoko
Matsue, Yuya
Naito, Ryo
Hiki, Masaru
Daida, Hiroyuki
Funding for this research was provided by:
AstaReal Co., Ltd.
Grant-in-Aid for Scientific Research (26507010)
Japan Society for the Promotion of Science (JP17K09527, JP18K15904)
The Intractable Respiratory Diseases and Pulmonary Hypertension Research Group from the Ministry of Health, Labor and Welfare (H29-027)
MEXT∗-Supported Program for the Strategic Research Foundation at Private Universities (2014–2018)
Article History
Received: 29 July 2020
Accepted: 25 September 2020
First Online: 6 October 2020
Compliance with ethical standards
:
: Drs. Sato, Ishiwata, Matsue, Naito, and Kasai are affiliated to a department endowed by Philips, Fukuda Denshi, and ResMed. Dr. Daida received manuscript fees, research funds, and scholarship funds from Kirin Co. Ltd., Kaken Pharmaceutical Co. Ltd., Abbott Japan Co. Ltd., Astellas Pharma Inc., Astrazeneca K.K., Bayer Yakuhin Ltd., Boston Scientific Japan K.K., Bristol-Myers Squibb, Daiichi Sankyo Company, MSD K.K., Pfizer Inc., Philips, Sanofi K.K., and Takeda Pharmaceutical Co. Ltd. Other authors report no conflicts of interest.
: This study was approved by the Juntendo University Hospital Institutional Review Board (#14-019). This is a research involving Human Participants.